Facebook link Linked In link You Tube link
  • Education2015

    Share Your Science

    Attendees from around the globe share their research and advance their careers. See their work

  • Industry2015

    Industry Partnership

    FOCIS provides a plethora of opportunities for industry to interact with immunology experts from around the world. Learn more.

  • Science Immunology Homepage Slider

    New Journal Showcasing Innovative Advances


    FOCIS members receive complimentary access to the journal. Read the current issue.
  • 2016AdvCourseSunglasses

    2017 Advanced Course Registration Now Open!

    The ever-popular Advanced Course is headed back to Scottsdale, AZ from February 19-22. Register now!

The Federation of Clinical Immunology Societies (FOCIS) exists to improve human health through immunology by fostering interdisciplinary approaches to both understand and treat immune-based diseases. Initially established as a cross-disciplinary meeting, FOCIS held its first Annual Meeting in 2001 and we look forward to seeing you at our 17th Annual Meeting in Chicago, Illinois!  

News & Information

Just Announced! Clinical Immunology Trainee Award

Together with FOCIS, Clinical Immunology has established the Clinical Immunology Trainee Award for a colleague in training (student or fellow) to be selected among those who submit abstracts to the FOCIS Annual Meeting.

Read more...

New! Cancer Course Held Before FOCIS 2017

FOCIS is collaborating with the Society for Immunotherapy of Cancer (SITC) to offer a course on Cancer Immunity and Immunotherapy in advance of FOCIS 2017 on Wednesday, June 14 in Chicago. 

The course will review the scientific basis and current practices of cancer immunotherapy, with emphasis on principles, recent advances as well as
prospects, limitations, and future scientific needs. 

The course is designed for...

Read more...

All Articles...

 

 FOCIS 2017 Sponsors

 

 

ePub header 2016

December 22, 2016
 
EDITOR: Andrew H. Lichtman, MD, PhD, Brigham & Women's Hospital  EDITORIAL BOARD: Abul K. Abbas, MD, University of California, San Francisco | Carla J. Greenbaum, MD, Benaroya Research Institute | Andrew H. Lichtman, MD, PhD, Brigham & Women's Hospital

Highlights from Recent Literature

circlearrow2 Early Dysregulation Leads to Autoimmune Disease in Adults
 

Antibodies against self-proteins can be present for years to decades before the development of overt autoimmune disease, suggesting that a loss of tolerance may exist amongst circulating immune cells that precedes tissue injury. The authors studied autoimmunity in a mouse model of Sjögren’s disease in order to identify the type and timing of immune dysregulation that made these mice susceptible to inflammatory disease later in life.

readmore

 
  Reviewed by Rachael A. Clark, MD, PhD, Brigham and Women's Hospital

 

Developments in Basic Immunology and Novel Therapies

circlearrow2 Exploiting Metabolism in T cells to Treat Immune Mediated Disease
 

Over the previous decade, several groups have elucidated details of metabolic pathways that drive survival, growth and differentiation in T lymphocytes1,2. T cells differ in their utilization of metabolic pathways and therefore energy sources depending on the specifics of T cell subset and state of activation. The bio-energetics needs of a resting naïve lymphocyte are different from one that is rapidly expanding and differentiating or actively regulating immune responses. It is now clear that this influences the quality and immune responses.

readmore

 
  Submitted by Jonathan S. Maltzman, MD, PhD, FAST, Veterans Affairs Palo Alto Health Care System and Stanford University

 

Selected Recent Clinical Trial Results

circlearrow2 Activity of Secukinumab, an Anti-IL-17A Antibody, on Brain Lesions in RRMS: Results From a Randomized, Proof-Of-Concept Study
 

Clinical Trial: Havrdova E, Belova A, Goloborodko A, et al. J Neurol (May 2016) 263:1287-1295

Disease: relapsing remitting multiple sclerosis (RRMS)

Intervention: secukinumab 10 mg/kg or placebo. Secukinumab is a human monoclonal antibody that binds to IL-17A

 

readmore

 
  Submitted by Sandra Lord, MD, Benaroya Research Institute. Edited by Carla J. Greenbaum, MD, Benaroya Research Institute


   

Share